NY-WEBBING
5.4.2022 14:03:04 CEST | Business Wire | Press release
Webbing , a global MVNO (Mobile Virtual Network Operator) connectivity provider for enterprise mobility and IoT, today announced the immediate availability of WebbingCTRL , a fast and simple global-ready connectivity solution. WebbingCTRL is the only SIM in the world that can easily and remotely become any wireless carrier’s SIM, eliminating network provider lock-in and providing complete control over connectivity with zero-touch provisioning.
IoT connectivity can require substantial costs and time to orchestrate the implementation of network providers. Additionally, IoT use cases are rapidly changing, so organizations need a way to make future-proof decisions today in order to handle connectivity challenges on the horizon. Using the WebbingCTRL platform, organizations can easily add, remove, and swap the carrier for any number of IoT or enterprise deployments to another wireless carrier of their choice with which they have an eSIM subscription. There’s no need for carrier integration.
The IoT environment is accelerating, and connectivity solutions need to adapt to fast-moving deployments now and in the future. The WebbingCTRL eSIM delivers total flexibility to ensure devices have reliable connectivity, anywhere in the world. The ability to remotely provision devices without extra carrier integration or collaboration also vastly reduces time-consuming deployment cycles and could have a huge impact on the ability to scale.
The WebbingCTRL solution eSIM is device agnostic and comes in any form factor. As a result, businesses can gain complete control over connectivity for a wide array of use cases, including:
- Enterprise employee mobile connectivity: Enables organizations to provide seamless connectivity for employees as they cross national boundaries and enter areas where one carrier may have better coverage than another.
- Transportation and logistics : Enable IoT tracking devices to switch automatically from a private network in a warehouse to a public network when in transit.
- Mission-critical IoT: Prevent interruption to operations that depend on connectivity when one carrier’s coverage is down by switching automatically to another.
- Automotive: Connected vehicles need constant connectivity and they cannot always use a roaming carrier due to regional connectivity regulations. WebbingCTRL can automatically change carriers as vehicles cross into new coverage areas or national borders.
“With WebbingCTRL, companies can finally take complete control of their connectivity to ensure business continuity, take advantage of better pricing and coverage and avoid having to physically touch hundreds, even thousands of devices to change carriers,” said Noam Lando, co-founder and CEO at Webbing. “Companies can securely control all their devices’ connectivity, with the confidence to connect anywhere in the world, 24-7, both now and in the future.”
Because WebbingCTRL works independently of SM-DP and SM-SR infrastructure, the carrier change takes place almost immediately, and the eSIM will act just as if the SIM card had been physically changed to the new carrier. And WebbingCTRL is not limited to public networks but can also be used to manage connectivity to private networks.
Additionally, companies can set up business rules that will automatically change the carrier under specific conditions, such as location, country, loss of connectivity or even after a certain amount of time.
For more information about WebbingCTRL and ways to streamline your IoT deployment, contact sales@iamwebbing.com .
About Webbing
Webbing is a global data MVNO that delivers innovative enterprise grade, global connectivity and IoT services. Our secured network of 600+ mobile carriers across more than 200 countries, ensures superior data connectivity between businesses, people, and things wherever the device is located.
Since our foundation in 2010, we have been developing revolutionary SIM technology, powerful management platforms and a robust global network that revolutionize your data, making it relevant and actionable. Our leading-edge solutions deliver a streamlined, centralized, and scalable means of deploying and managing organizations' global fleet of devices. Our experts assist in every step of the device on boarding process to ensure you are set up to meet your organization’s connectivity needs. For more information, visit https://www.webbingsolutions.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005430/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom